A Study Protocol to Assess the Determinants of Glycaemic Control, Complications and Health Related Quality of Life for People with Type 2 Diabetes in Saudi Arabia

Mohammed J Alramadan1, Afsana Afroz1, Mohammed Ali Batais5, Turky H Almigbal5, Hassan Ahmad Alhamrani5, Ahmed Albaloshi4, Fatimah A Alramadan3, Dianna J Magliano5 and Baki Billah2*

1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
2College of Medicine, King Saud University, Riyadh, Saudi Arabia
3Diabetes Centre, Directorate of Health Affair, Hofuf, Saudi Arabia
4Diabetes Centre, Directorate of Health Affair, Jeddah, Saudi Arabia
5Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

Abstract

Background: The prevalence of type 2 diabetes mellitus is high in Saudi Arabia, and a large proportion of those affected by the disease are not controlling their blood sugar, which exposes them to diabetes complications. The aim of this study is to evaluate factors associated with poor glycaemic control, complications and poor quality of life among people with type 2 diabetes in Saudi Arabia.

Methodology: Using a cross-sectional study design, 1082 participants with type 2 diabetes attending diabetes centres in Riyadh, Jeddah and Hofuf will be recruited in the study. They will be interviewed to complete a pre-tested electronic questionnaire. The questionnaire collects information related to socio-demographics, medical history, lifestyle, family support, utilisation of healthcare services, anxiety, depression, quality of life, cognitive function, independence in daily living activity, neuropathy, anthropometric measures, up-to-date documented lab test results and current medication. Data will be summarised and presented as mean ± standard deviation (or median and percentiles) for numerical data and frequency and percentage for categorical data. T-test, ANOVA and chi-square tests will be used to explore associations between risk factors and outcomes. Any association will be evaluated further using regression analysis.

Discussion: Knowledge of the risk factors pertaining to poor glycaemic control, diabetes complications and poor quality of life for people with type 2 diabetes is crucial. This knowledge will assist healthcare providers to identify and provide more intensive care plans to those who need it, as well as guide the development of new strategies to improve management of the disease. This will improve the health of people with type 2 diabetes and lower their risk of complications, and reduce the burden of this highly prevalent disease on families and the community.

Keywords: Type 2 diabetes; Saudi Arabia; Glycaemic control; Complication; Quality of life

Introduction

Diabetes mellitus is one of the most common chronic non-communicable diseases [1,2]. An estimated 415 million adults had diabetes worldwide in 2015 and this number is expected to rise to 642 million by 2040 [3]. In 2015, approximately five million individuals between the age of 20 and 79 years died because of diabetes [3]. Furthermore, roughly 14.5% of global all-cause mortality among adults is attributed to diabetes and half of these deaths occur among those aged below 60 [3].

Similar to other countries in the Middle East, modernisation has taken its toll on the population of Saudi Arabia. The vast lifestyle changes of Saudis over the last few decades, accompanied by rising rates of obesity, have led to a rapid and progressive increase in the prevalence of diabetes. A recent study showed that 13.4% of Saudis aged 15 years and above have diabetes, which is significantly higher than both the global prevalence (8.8%) and the prevalence in the Middle East (10.7%) [3,4].

The control of blood glucose levels is the cornerstone of diabetes management. Studies have shown that there is a strong association between an elevated blood glucose level and the risk of diabetes-related complications and mortality for people with diabetes [5,6]. Of particular concern is that between 50% and 70% of people with type 2 diabetes mellitus (T2DM) in Saudi Arabia have uncontrolled blood glucose levels [7-9], and the prevalence of diabetes-related complications among them is high [10-13].

A few studies that have examined factors affecting glycaemic control for people with T2DM in Saudi Arabia have indicated poor control to be associated with increasing age, insulin use, smoking, lower levels of physical activity, poor diabetes self-care behaviour, low adherence to medicine, anxiety and depression [7-9]. A number of other factors that may have an impact on glycaemic control, diabetes complications and quality of life-such as the duration of diabetes, family support, cognitive function and lifestyle factors (diet and physical activity)-were not investigated adequately in existing studies from Saudi Arabia [14-16].

Furthermore, it is well-established that haemoglobin A1c (HbA1c) is a more accurate measure of blood sugar control, compared to fasting
and random blood sugar measurements, because HbA1c reflects the level of glycaemic control over several weeks [17]. However, some of the studies from Saudi Arabia used random blood sugar for determining the level of control, which was a limitation to these studies. In addition, the majority of studies from Saudi Arabia involved a single centre, or were hospital-based [8-10,13,18-26] and may not accurately represent the large and diverse population of the country.

To address the above gaps, a multi-centre study is required which will comprehensively investigate the effect of all possible risk factors. Thus, the aim of this proposed study is to conduct a multi-centre study in Saudi Arabia to explore the effect of lifestyle factors, family support and cognitive impairment, as well as other risk factors for glycaemic control, diabetes complications and quality of life for people with T2DM mellitus (T2DM). The knowledge of these risk factors will help healthcare providers, the individuals with the disease, and society as a whole. Understanding the burden of the associated risk factors is also important for public health policymakers who develop healthcare priorities that yield the greatest benefits.

Objectives

This study has three main objectives. Firstly, to evaluate the determinants of poor glycaemic control among people with T2DM in Saudi Arabia. Secondly, to investigate the prevalence of coronary artery disease, neuropathy, nephropathy and cognitive impairment, as well as their associated factors among people with T2DM. Thirdly, to examine factors associated with poor health-related quality of life for people with T2DM. Furthermore, secondary objectives of this study is to examine factors associated with poor control of blood pressure as well as dyslipidaemia among people with T2DM.

Methodology

Ethical approval

Both the Monash University Human Research Ethics Committee and the Research Ethics Committee of the Ministry of Health in Saudi Arabia approved this project. The approval of the College of Medicine Institutional Review Board at King Saud University was also obtained.

Study design

A cross-sectional study will be conducted to address the research questions. Cross-sectional study design has the advantage of being inexpensive and time-consuming compared to other epidemiological study designs. Moreover, in using this study design, the prevalence of outcomes such as poor glycaemic control and complications, as well as the prevalence of risk factors, can be measured.

Study population

The study population will consist of people with T2DM in Saudi Arabia attending diabetes centres in the cities of Hofuf, Riyadh and Jeddah (Figure 1). These cities are among the top most populated in the country and their diabetic centres serve a mixture of people who come from urban, as well as rural settings. Inclusion criteria include confirmed diagnosis of T2DM, age 18 years and above and duration of diabetes of one year and more. Participants will be excluded if they have other types of diabetes (type 1 or gestational), or if there is no HbA1c test results in their medical records for the past 6 months. Pregnant women will also be excluded.

Sample size

A total of 1082 subjects with T2DM will be recruited for the study which was calculated based on 90% power, 5% significance level and a margin of error of 2.5% for prevalence of glycaemic control. A back calculation of power shows that a sample size of 1082 participants will maintain a power of 90% or above for all other primary and secondary objectives of this study.

Recruitment

A systematic random-sampling method will be used to recruit participants. The number of participants recruited each day is expected to be 10. Every day during the data-collection period, the data collectors will begin by randomly selecting a participant with T2DM from the first K participants attending the diabetes centre and invite them to participate. The value of K will depend on the number of people attending the centre every day, which varies between centres. Following on, every K-th patient will be approached. If the K-th person declines or does not have T2DM, the next person will be invited. The recruitment will be continued for a period of six months or until data have been collected from 1082 patients, whichever comes first.

Informing participants about the study and obtaining the consent

Data collectors will fully inform each of the participants about the purpose of the study, how the data will be collected and how the collected information will be used while maintaining participants’ confidentiality. Then, participants will be given an explanatory statement and allowed some time to read and ask questions. Upon their agreement to participate, they will be required to read and sign a consent form.

Data collection instrument

A pre-tested questionnaire will be used to collect data. The original English version of the questionnaire has been translated into Arabic. The Arabic version was then translated into English to check that the Arabic and the original English versions have exactly the same meanings. Prior to collecting the data, data collectors will be trained by the primary investigator on how to approach participants, inform participants about the study, fill in the electronic questionnaire and take the anthropometric measurements.

Research Electronic Data Capture (REDCap) will be used to collect and manage the data [27]. REDCap is a secure web-based application...
for constructing electronic surveys and collecting data for research studies. It provides a user-friendly interface with validated data entry, audit trails for tracking data manipulation, and an automated export procedure for seamless data downloads to common statistical software packages.

Using a standard questionnaire, the following information will be collected for all participants:

- Diabetes centre and data collector details.
- Participant's socio-demographics data, including name, age, gender, marital status, education, nationality, work status and household income.
- Medical history: duration of diabetes, place of follow-up, frequency of follow-up, diabetes treatment, self-monitoring blood glucose, hypoglycaemic events, medical history of other diseases, diabetes complications and medication adherence (Morisky Medication Adherence questionnaire).
- Family support for diabetes, utilisation of healthcare services, knowledge of HbA1c.
- Lifestyle data including smoking status, dietary habits (UK diabetes and diet questionnaire at: https://sp.surveys.ac.uk/the-uk-diabetes-and-diet-questionnaire-ukdqq) and physical activity (WHO STEPS questionnaire for diet at: http://www.who.int/chp/steps/STEPS_Instrument_v2.1.pdf).
- Psychological aspect data that include depression (the Patient Health Questionnaire-2 (PHQ-2)) [28] and anxiety (Generalized Anxiety Disorder Scale (GAD-2)) [29].
- Patient's quality of life (EQ-5D-5L) [30] and independence regarding activities in daily life (Katz Index) [31].
- Rowland Universal Dementia Assessment Scale (RUDAS) [32].
- Neuropathy screening tool (the Michigan Neuropathy Screening Instrument [33]).
- Anthropometrics: height, weight, blood pressure and waist and hip circumference.
- Materials and equipment: digital scale, measuring tape, and digital automatic blood pressure monitor.

- Height: height will be measured for all participants using a portable stadiometer. Standing height is measured with the subject in bare feet, back-square against the wall and eyes looking straight ahead. A set square resting on the scalp and a tape measurement from the wall/bed is used to measure height to the nearest 0.5 cm. This will be done twice and if the measurement varies more than 2 cm, a third measurement will be taken. A stool will be used where necessary.
- Weight: participant will be instructed to remove their shoes and outer layers of clothing (such as jackets or jumpers). Weight will be recorded to the nearest 0.1 kg.
- Waist circumference: will be measured against thin clothing (for cultural reasons), on exhalation, midway between the lower rib margin and the anterior superior iliac spine (hip bone) or narrowest abdominal point. Subject should be relaxed with arms held loosely at sides. The tape measure must be kept horizontal for standing measurement. This will be done twice and if the measurement varies by more than 2 cm, a third measurement will be taken. The waist circumference will be recorded to the nearest 0.5 cm.
- Hip circumference: measure at the widest circumference around the hip bones, so that the tape passes over the greatest protrusion of the gluteal muscles. The tape measure must be kept horizontal for standing measurement. This will be done twice and if the measurement varies more than 2 cm, a third measurement will be taken. The hip circumference will be recorded to the nearest 0.5 cm.
- Blood pressure: participants should be seated for at least five minutes, legs uncrossed, feet flat on the floor and any excess clothing items that may interfere with measurement must be removed. Three systolic and diastolic blood pressure readings will be taken using an automated blood pressure monitor machine.
- Information from patients' medical records, including the three most recent blood pressure measures, fasting blood sugar measures, HbA1c, serum creatinine, albumin/creatinine ratio, eGFR, lipid profile, current prescribed medications and documented diagnosis of hypertension, coronary artery disease and stroke.

Data management and analysis

During the data-collection period, the data will be saved in the secure REDCap web-based application hosted by Monash University. The application is accessible only by the research team. When the data collection is completed the data will be exported to the IBM SPSS statistical package and will be saved on the secure School of Public Health and Preventive Medicine at Monash University allocated network storage (Monash (S:) drive). Participants' names will be removed from the database and each participant will be identified by a numeric code generated by REDCap. The database containing all information will be saved in a separate secure electronic folder, which will not be used for data analysis. Only the research team will have access to the identified and de-identified electronic databases.

Data will be summarised and presented as either mean ± standard deviation or median and percentiles for numerical data and frequency, and percentage for categorical data. Depending on the type of data, t-test, ANOVA, nonparametric tests or chi-square tests will be used to examine for associations between risk factors and outcomes. Any association will be further evaluated using simple and multiple logistic regression analysis.

Outcomes assessment

Definitions of the main study outcomes that will be considered:

- Glycaemic control: the proportion of the glycosylated haemoglobin (HbA1c) measured as a percentage and categorised as good control (HbA1c<7.0%), reasonable control (HbA1c 7%-8%) and poor control (HbA1c>8.0%).
- Nephropathy: documented eGFR (calculated by the CKD EPI formula) below 90 ml/min (categorised as mild renal impairment (60-89 ml/min), moderate renal impairment (30-59 ml/min), severe renal impairment (15-29 ml/min) and renal failure (<15 ml/min).
- Coronary artery disease: documented diagnosis of coronary artery disease (CAD).
Neuropathy: a score of 7 or more using the Michigan Neuropathy Screening Instrument.

Quality of life: EQ-5D-5L health states scores will be converted into a single index value between 0 and 1, and the quality of life will be categorised as Good quality of life (0.67–1.00), fair quality of life (0.34–0.66) and poor quality of life (≤ 0.33).

Hypertension: either a documented diagnosis of hypertension, on antihypertension medications or three previous high blood pressure readings (systolic ≥ 140 and diastolic ≥ 90). Persons with poor blood pressure control are defined as having hypertension and their current systolic blood pressure as ≥ 140 mm Hg or diastolic ≥ 90 mm Hg.

Dyslipidaemia: Documented total cholesterol>4.0 mmol/L, low density lipoproteins (LDL)>2.0 mmol/L, high density lipoprotein (HDL)<1.0 mmol/L, triglycerides>2.0 mmol/L or taking lipid lowering medication.

Impaired cognitive function is defined as a score of ≤ 22 in the Rowland Universal Dementia Assessment Scale (RUDAS).

Pilot Study

The questionnaire was piloted on 29 participants attending diabetes centre in Hofuf over a period of two weeks. The sociodemographic characteristics of the participants in the pilot study are presented in Table 1. Mean age was 55.7 (± 11.6) years. Approximately 38% of participants were female and the majority of participants were married (93.1%). Roughly a quarter (24.1%) of participants was illiterate and 41.4% had only achieved primary school (82.8%) reside in Hofuf city, while the rest lived in remote villages. With regard to work status, 17.2% worked and 34.5% were homemakers (house-wives). The rest of the participants were either retired (27.6%) or not working (20.7%). A large proportion of participants (41.4%) had a total household income between 3000 and 6000 Saudi Riyals.

A summary of some disease characteristics and main study outcomes is presented in Table 2. Participants had a mean duration of diabetes of 17.7 (± 10.5) years. Mean HbA1c was 9.6% (± 2.0%). The majority of participants (69.0%) had poor glycaemic control (HbA1c>8), while 10.3% had good control (HbA1c ≤ 7%) and 17.2% had reasonable control (HbA1c 7.1%-8.0%). More than half (HbA1c>8), while 10.3% had good glycaemic control (HbA1c ≤ 7%) and 17.2% had reasonable control (HbA1c 7.1%-8.0%). More than half (HbA1c>8), while 10.3% had good glycaemic control (HbA1c ≤ 7%) and 17.2% had reasonable control (HbA1c 7.1%-8.0%). More than half of the participants (58.6%) had dyslipidaemia and close to half (48.3%) had hypertension, while the diagnosis of CAD was documented in 31.0% of participants. Using the Michigan Neuropathy Screening Instrument, 31.0% of participants had a score (≥7), suggestive of neuropathy. eGFR calculated from most recent serum creatinine showed that 55.2% of participants had some renal impairment. Of those, 27.6% had mild impairment, 24.1% had moderate impairment, and 3.4% had severe impairment. Cognitive function was impaired in about half (51.7%) of participants using the Six-item Cognitive Impairment Test (6CIT) [34]. The quality of life was fair for 34.5% and poor for 3.4% of participants, while the majority (62.1%) had good quality of life. There were some missing values in some important investigations including HbA1c, cholesterol and triglycerides. The range of missing values was between 3.4% for HbA1c and 5.0% for triglycerides.

The questionnaire was found to be acceptable by most of the participants and practical by data collectors. However, the average time required to complete data collection for one participant was more than one hour. In order to ensure the collection of data from the planned number of participants, the length of the questionnaire was reduced after the completion of the pilot study. The STOP-BANG Sleep Apnea and the chest pain (Rose) questionnaires were removed [35,36]. Questions related to the duration of complications reported by participants were also removed.

Based on our findings in the pilot study that a relatively large proportion of people were illiterate, a decision was made to use the Rowland Universal Dementia Assessment Scale (RUDAS) instead of the Six-item Cognitive Impairment Test (6-CIT) to evaluate cognitive function. RUDAS is a multicultural cognitive assessment tool that is not affected by literacy level, and has been validated among Arabic-speaking people [32,37]. Approval to use the amended questionnaire was obtained from all ethical committees that have approved this project.

Discussion

This project is a comprehensive multi-centre study that will improve our understanding of the factors associated with poor control of blood glucose level, the factors that increase risk of diabetes complications and the factors associated with poor quality of life among people with T2DM in Saudi Arabia. The anticipated valuable information that will be obtained from this study will help healthcare providers to identify people with diabetes who are at risk of poor control and complications, and the factors associated with poor quality of life.
and provide them with more intensive care plans. It will also identify priority issues that will guide the development and implementation of new national strategies to promote the health of people with T2DM in Saudi Arabia.

The strength of this study lies on the relatively large number of participants and the recruitment from three highly populated cities in three different regions of Saudi Arabia. The evaluation of a wide range of risk factors and outcomes using validated tools also provide strength to this study. Since this study is cross-sectional, we will be assessing association; no causal relation can be inferred. Observational study designs are also prone to bias. Nevertheless, this study will not only provide valuable information that will be used by healthcare providers and health policy makers, but will also generate hypotheses that will guide future advance research projects in the field of diabetes in Saudi Arabia, in the Middle East region and globally.

### Competing Interests

All authors declare that they have no competing interests.

### Author Contributions

All authors were involved in the conception and design of the study. MJA and AA reviewed the literature and MJA drafted the manuscript. All authors critically reviewed the manuscript and approved the final version.

### References


<table>
<thead>
<tr>
<th>Variable</th>
<th>Descriptive statistics</th>
<th>Variable</th>
<th>Descriptive statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes duration in years (mean ± SD)</td>
<td>17.7 ± 10.5</td>
<td>Hypertension %</td>
<td>No</td>
</tr>
<tr>
<td>HbA1c % (mean ± SD)</td>
<td>9.6 ± 2.0</td>
<td>CAD %</td>
<td>No</td>
</tr>
<tr>
<td>Glycaemic control %</td>
<td>Good</td>
<td>3(10.3%)</td>
<td>Reasonable</td>
</tr>
<tr>
<td>Quality of life %</td>
<td>Good</td>
<td>18(62.1%)</td>
<td>Fair</td>
</tr>
<tr>
<td>Cognitive impairment %</td>
<td>No</td>
<td>14(48.3%)</td>
<td>Yes</td>
</tr>
<tr>
<td>Dyslipidaemia %</td>
<td>No</td>
<td>12(41.4%)</td>
<td>Yes</td>
</tr>
<tr>
<td>Neuropathy %</td>
<td>No</td>
<td>20(69.0%)</td>
<td>Mild</td>
</tr>
<tr>
<td>Nephropathy %</td>
<td>No</td>
<td>13(44.8%)</td>
<td>Mild</td>
</tr>
</tbody>
</table>

**Table 2:** Characteristics related to diabetes, complications and health related quality of life.


